A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best-supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission
This study will enroll approximately 460 subjects, aged 55 or older, with a diagnosis of de
novo AML (Acute Myeloid Leukemia) or AML secondary to prior myelodysplastic disease or
chronic myelomonocytic leukemia (CMML), and who have achieved first Complete remission (CR)/
Complete remission with incomplete blood count recovery (CRi) following induction with or
without consolidation chemotherapy. Subjects who have previously achieved CR/CRi with a
hypomethylating agent will be excluded from the study.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society